Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
E-Century Publishing Corp
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease caused by clonal expansion of one or more hematopoietic stem cell (HSC) lines due to a somatic mutation of the phosphatidylinositol glycan anchor (PIG-A) gene located on Xp22.1. PNH incidence is 1.5-2 cases per million of the population per year. PNH can affect multiple systems in the body and requires multidisciplinary clinical management. Patients can manifest with severe pancytopenia, life-threatening thrombosis affecting the hepatic, abdominal, cerebral, and subdermal veins, and high requirements for blood transfusion due to haemolytic anemia. PNH can also be associated with bone marrow failure. Advances in diagnostic techniques and a targeted therapeutic approach for PNH have emerged in the last two decades. Eculizumab, a promising humanized monoclonal antibody against C5, is the first approved therapy for PNH.
Açıklama
Anahtar Kelimeler
Paroxysmal nocturnal hemoglobinuria, diagnosis, treatment, eculizumab
Kaynak
American Journal of Blood Research
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
5
Sayı
1
